海通国际03月28日发布研报称,给予药明康德(603259.SH)优于大市评级,目标价格为81.60元。评级理由主要包括:1)收入端剔除新冠商业化项目保持高速增长态势;2)公司持续实施“长尾”战略并不断提高大药企份额。风险提示:中美地缘政治风险升级致海外业务受限,业务不达预期风险;行业竞争恶化风险;药企研发费用下降风险;汇率波动风险;核心技术人员流失。 AI点评:药明康德近一个月获得12份券商...
Source Link海通国际03月28日发布研报称,给予药明康德(603259.SH)优于大市评级,目标价格为81.60元。评级理由主要包括:1)收入端剔除新冠商业化项目保持高速增长态势;2)公司持续实施“长尾”战略并不断提高大药企份额。风险提示:中美地缘政治风险升级致海外业务受限,业务不达预期风险;行业竞争恶化风险;药企研发费用下降风险;汇率波动风险;核心技术人员流失。 AI点评:药明康德近一个月获得12份券商...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.